Phase II AIDS malignancy consortium trial of topical halofuginone in AIDS-related kaposi sarcoma

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages 64-68

  Koon, Henry B ^a   Fingleton, Barbara ^b   Lee, Jeannette Y ^c   Geyer, Julia T ^d   Cesarman, Ethel ^d   Parise, Robert A ^e   Egorin, Merrill J ^e   Dezube, Bruce J ^f   Aboulafia, David ^g   Krown, Susan E ^h  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; COLLAGEN TYPE 1; GELATINASE A; HALOFUGINONE; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; MATRIX METALLOPROTEINASE; NSC 713205; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

ADMINISTRATION, TOPICAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; QUINAZOLINONES; SARCOMA, KAPOSI; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 78650691586     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181fc0141     Document Type: Article

References (24)

1. Schalling M, Ekman M, Kaaya EE, et al. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med. 1995;1: 707-708.
2. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA. 1999; 96:4546-4551.
3. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994; 266:1865-1869.
4. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/ vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA. 1997;94:979-984.
5. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA. 1990;87:4068-4072.
6. Sturzl M, Roth WK, Brockmeyer NH, et al. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA. 1992;89:7046-7050.
7. Sturzl M, Brandstetter H, Zietz C, et al. Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene. 1995;10:2007-2016.
8. Skobe M, Brown LF, Tognazzi K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol. 1999;113: 1047-1053.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
10. Qian LW, Xie J, Ye F, et al. Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol. 2007; 81:7001-7010.
11. Toschi E, Barillari G, Sgadari C, et al. Activation of matrix-metal-loproteinase-2 and membrane-type-1-matrix-metalloproteinase in endo-thelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell. 2001;12:2934-2946.
12. Seandel M, Noack-Kunnmann K, Zhu D, et al. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood. 2001;97:2323-2332.
13. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. Faseb J. 2000;14:2477-2485.
14. Nagler A, Miao HQ, Aingorn H, et al. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol. 1997;17:194-202.
15. Liu K, Sekine S, Goto Y, et al. Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro. Heart Vessels. 1998;13:18-23.
16. Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate. 2002;51:73-83.
17. Granot I, Halevy O, Hurwitz S, et al. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta. 1993;1156:107-112.
18. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:47-64.
19. Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res. 2007;328:153-166.
20. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002;20:153-159.
21. Parise RA, Sparrow BR, Merrill JW, et al. Liquid chromatography- electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;810:35-40.
22. Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science. 2009;324:1334-1338.
23. Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol. 2006;24:1389-1394.
24. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2005;23:982-989.